Form 4: HealthEquity Director Adrian Dillon Boosts Stake with RSU Grant
Insider Transaction Report
HealthEquity, Inc. Director Adrian T. Dillon acquired 2,003 shares of common stock through a restricted stock unit grant, increasing his total beneficial ownership to 59,518 shares.
Summary
- Adrian T. Dillon, a Director of HealthEquity, Inc. (HQY), acquired 2,003 shares of common stock on June 26, 2025.
- The acquisition was through a restricted stock unit (RSU) grant, which represents a contingent right to receive one share of the issuer's common stock.
- The restricted stock units are set to vest in full on the date of HealthEquity, Inc.'s next annual stockholder meeting, with vested shares to be delivered upon vesting.
- Following this transaction, Mr. Dillon's direct beneficial ownership of common stock increased to 59,518 shares.
- Mr. Dillon also holds several immediately exercisable stock options: 7,632 options at an exercise price of $32.50 expiring on September 1, 2026; 4,837 options at $46.40 expiring on February 1, 2027; 4,339 options at $50.41 expiring on February 1, 2028; 3,626 options at $63.64 expiring on February 1, 2029; and 4,012 options at $66.06 expiring on February 1, 2030.
Sentiment
Score: 6
Explanation: The filing indicates a routine grant of restricted stock units to a director, which is a common form of compensation and aligns the director's interests with shareholders. It does not contain any negative or unexpected information.
Positives
- Director Adrian T. Dillon increased his direct beneficial ownership of HealthEquity, Inc. common stock by 2,003 shares through a restricted stock unit grant.
- The acquisition of additional shares aligns the director's interests more closely with those of the shareholders.
- Mr. Dillon continues to hold a significant number of shares (59,518) and exercisable stock options, demonstrating continued commitment to the company.
Future Outlook
The 2,003 restricted stock units granted to Director Adrian T. Dillon are scheduled to vest in full on the date of HealthEquity, Inc.'s next annual stockholder meeting.
Industry Context
This filing is a routine disclosure of an insider transaction, specifically a grant of equity compensation to a director, which is a common practice across various industries to align management and board interests with shareholder value.
Stakeholder Impact
- Shareholders: Increased alignment of director's interests with shareholder value due to increased equity ownership.
Next Steps
- Vesting of the 2,003 restricted stock units on the date of HealthEquity, Inc.'s next annual stockholder meeting.
Key Dates
| Date | Description |
|---|---|
| 02/05/2024 | Date Power of Attorney given by Mr. Dillon was previously filed with the U.S. Securities & Exchange Commission. |
| 06/26/2025 | Date of transaction for the acquisition of 2,003 shares of common stock via restricted stock unit grant. |
| 06/30/2025 | Signature date of the reporting person's attorney-in-fact. |
| 09/01/2026 | Expiration date for 7,632 stock options with an exercise price of $32.50. |
| 02/01/2027 | Expiration date for 4,837 stock options with an exercise price of $46.40. |
| 02/01/2028 | Expiration date for 4,339 stock options with an exercise price of $50.41. |
| 02/01/2029 | Expiration date for 3,626 stock options with an exercise price of $63.64. |
| 02/01/2030 | Expiration date for 4,012 stock options with an exercise price of $66.06. |
Keywords
HealthEquity, HQY, Adrian Dillon, Form 4, insider transaction, beneficial ownership, restricted stock units, stock options, director compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.